

Allium Medical Solutions

Business update

It is all about business execution

Pharma & biotech

Gardia Medical's Wirion device is on track for FDA submission, expected by end-2017; approval is possible in Q218. If approved, it would become the only embolic protection system for all atherectomy procedures in the legs which we think will help to reach a strategic transaction. Furthermore, Allium Stents and IBI Medical are expected to gain approval in Russia in 2018 while approval in China is expected in early 2018. We expect initial revenues from Mexico in Q417 and from the strategic agreement in Russia in H118. In addition, Allevetix is due to start a clinical trial in the next few months and TruLeaf is progressing its large animals study. Our updated valuation is NIS1.68/share.

Year	Revenue	PBT*	EPS*	DPS	P/E	Yield
end	(NISm)	(NISm)	(NIS)	(NIS)	(x)	(%)
12/15	5.2	(18.5)	(0.65)	0.0	N/A	N/A
12/16	7.4	(22.0)	(0.49)	0.0	N/A	N/A
12/17e	9.7	(20.3)	(0.35)	0.0	N/A	N/A
12/18e	16.6	(7.3)	(0.10)	0.0	N/A	N/A

Note: *Normalised, excluding amortisation of acquired intangibles and exceptionals.

Gardia's Wirion system nears FDA submission

Gardia is pursuing US approval of its Wirion device following strong data from the WISE-LE trial which met its primary and secondary endpoints early. Positive data on debris capture has been released and will be presented at the ISET conference in Florida in February 2018. A 510(k) submission to the FDA is expected by the end of the year; an approval decision could come in Q218. If approved, Wirion would become the only protection system cleared for all atherectomy procedures in the US. The companyis advancing towards a strategic transaction for Gardia. We model Wirion revenue of NIS2.8m after full launch in 2018e, to NIS8.6m in 2020e.

Sales in key emerging markets on track for 2018

Allium has sent the full package for approval to the Chinese FDA(CFDA). We therefore expect marketing approval in China in early Q118 and the subsequent launch in FY18. Furthermore, the company has signed a distribution agreement for Colombia worth at least NIS3m over five years. Separately, Allium has received CE mark for a novel type of long urological stent. We maintain our near-term revenue forecast for stents of NIS9.7m in FY17 and NIS16.6m in FY18.

R&D gains visibility

Allevetix has received approval from the ethical committee to start a first-in-man (FIM) clinical trial, expected during Q118. The trial will test Allevetix's gastroduodenal sleeve for obesity and diabetes in 10-12 patients and will last for six months. In addition, TruLeaf has started a trial in large animals which is partly funded with a grant from the Israeli Innovation Authority.


Valuation: DCF of NIS119m or NIS1.68/share

In December Allium raised c NIS7m gross by issuing 5m new shares (c 7% of enlarged capital). We estimate that FY17e net cash of NIS21m provides runway at least until the end of 2018. Our DCF valuation of Allium is NIS119m (vs NIS124m) or NIS1.68/share (NIS1.89/share) as a result of updating the number of shares and net cash. Regional expansion remains keyfor Allium's investment case.

24 December 2017

Price*	NIS1.25
Market cap	NIS88m
* Priced at 20 December 2017	
Net cash (NISm) at December 2017	e 20.7
Shares in issue at December 2017	70.5m
Free float	49.6%
Code	ALMD
Primary exchange	TASE
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	(1.7)	13.1	0.4
Rel (local)	(4.8)	9.8	(3.9)
52-w eek high/low	N	IS1.4	NIS0.8

Business description

Allium Medical Solutions is a company focused on developing and marketing minimally invasive devices in various areas: cardiovascular, metabolic, genitourinary and gastrointestinal. The company has three selling product lines: Allium Stents, IBI (EndoFast) and Gardia Medical. Allium markets its products mainly through distribution agreements.

Next events

Regulatory approval in additional markets for Allium and IBI	H217
Start Allev etix first-in-man clinical trial	Q118
Gardia FDA submission	Q417

Analysts

Juan Pedro Serrate +44 (0)20 3681 2534 Jonas Peciulis +44 (0)20 3077 5728

healthcare@edisongroup.com

Edison profile page



	NIS'000 2014	2015	2016	2017e	2018
Year end 31 December	IFRS	IFRS	IFRS	IFRS	IFR:
PROFIT & LOSS					
Revenue	4,916	5,178	7,353	9,735	16,612
Cost of Sales	(5,699)	(4,421)	(5,171)	(7,501)	(9,914
Gross Profit	(783)	757	2,182	2,233	6,698
EBITDA	(20,373)	(16,333)	(20,377)	(19,492)	(6,772
Operating Profit (before GW and except.)	(20,758)	(16,759)	(20,759)	(19,893)	(7,133
Intangible Amortisation	(2,032)	(1,705)	(1,579)	(1,655)	(1,491
Exceptionals	(1,262)	(720)	(295)	0	(
Operating Profit	(24,052)	(19,184)	(22,632)	(21,548)	(8,624
Net Interest	(593)	(1,748)	(1,284)	(361)	(146
Exceptionals	0	0	0	0	(
Other	0	0	0	0	(
Profit Before Tax (norm)	(21,351)	(18,507)	(22,043)	(20,253)	(7,279
Profit Before Tax (IFRS)	(24,645)	(20,932)	(23,917)	(21,909)	(8,770
Tax	Ó	Ó	Ó	Ó	(
Profit After Tax (norm)	(21,351)	(18,507)	(22,043)	(20,253)	(7,279
Profit After Tax (IFRS)	(24,645)	(20,932)	(23,917)	(21,909)	(8,770
	18.43	28.53	44.97	57.73	70.50
Average Number of Shares Outstanding (m)		(0.65)		(0.35)	
EPS - normalised (NIS) EPS - IFRS (NIS)	(1.16)	` '	(0.49)	` '	(0.10
		(0.73)	(0.53)	(0.38)	(0.12
Dividend per share (NIS)	0.00	0.00	0.00	0.00	0.00
Gross Margin (%)	-16%	15%	30%	23%	40%
EBITDA Margin (%)	N/A	N/A	N/A	N/A	N/A
Operating Margin (before GW and except.) (%)	N/A	N/A	N/A	N/A	N/A
BALANCE SHEET					
Fixed Assets	28,218	25,612	23,616	21,660	19,908
Intangible Assets	26,438	24.059	22,465	20,810	19,319
Tangible Assets	1,780	1,472	1,025	725	464
Restricted cash	0	81	126	126	126
Current Assets	16,629	31,342	28.605	25,939	19,405
Stocks	2,330	2,277	2,516	2,249	2,664
Debtors	686	889	1,253	1,334	1,82
Cash	12,940	27,053	23,202	20,722	13,286
Other	673	1,123	1,634	1,634	1,634
Current Liabilities	(5,560)	(5,620)	(12,660)	(12,316)	(12,901
Creditors	(1,516)	(1,524)	(1,890)	(1,546)	(2,131
Accruals	(1,820)	(1,895)	(936)	(936)	(936
Other short termliabilities	(2,224)	(2,201)	(4,124)	(4,124)	(4,124
Long TermLiabilities	(7,127)	(6,207)	(1,368)	(1,268)	(1,168
Long termborrowings	(1,121)	(0,207)	(1,300)	(1,200)	(1,100
Other long termliabilities	(7,127)	(6,207)	(1,368)	(1,268)	(1,168
Net Assets	32,160	45,127	38,193	34,014	25,244
	32,100	45,127	30,193	34,014	25,244
CASH FLOW					
Operating Cash Flow	(19,026)	(15,874)	(17,259)	(20,010)	(7,235
Net Interest	0	0	0	0	(
Tax	0	0	0	0	(
Capex	(349)	(164)	(220)	(100)	(100
Acquisitions/disposals	0	0	0	0	(
Financing	25,191	31,992	13,956	17,730	(
Dividends	0	0	0	0	
Other	(41)	(1,841)	(328)	(100)	(100
Net Cash Flow	5,775	14,113	(3,851)	(2,480)	(7,435
Opening net debt/(cash)	(7,165)	(12,940)	(27,053)	(23,202)	(20,722
HP finance leases initiated	0	0	0	0	. (
Other	0	0	0	0	(
Closing net debt/(cash)	(12,940)	(27,053)	(23,202)	(20,722)	(13,286



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Limited (Edison NZ) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [4608589] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison hvestment Research Limited [4794244]. www.edisongroup.com

EDISON ISRAEL DISCLAIMER

Disclosure regarding the scheme to enhance the awareness of investors to public companies in the technology and biomed sectors that are listed on the Tel Aviv Stock Exchange and participate in the scheme (hereinafter respectively "the Scheme", "TASE", "Participant" and/or "Participants"). Edison Investment Research (Israel) Ltd., the Israeli subsidiary of Edison Investment Research Ltd (hereinafter respectively "Edison Israel" and "Edison"), has entered into an agreement with the TASE for the purpose of providing research analysis (hereinafter "the Agreement"), regarding the Participants and according to the Scheme (hereinafter" the Analysis" or "Analyses"). The Analysis will be distributed and published on the TASE website (Maya), Israel Sex Website (Maya), Israel S

EDISON INVESTMENT RESEARCH DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not quarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research Pty Ltd (Corporate Authorised Representative (125201) of Myonlineadisers Pty Ltd (AFSL. 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research Investment Research Pty Ltd (AFSL. 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research be interested as an investment adviser with the Securities and Exchange Commission. Edison US reliable to the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed by any subsoriber or prospective subsoriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subsoribe, or underwrite any securities mentioned or in the typic of his document. This document is provided by information purposes only and should not be construed as an offer or solicitation for